JP2022547483A5 - - Google Patents

Info

Publication number
JP2022547483A5
JP2022547483A5 JP2022514591A JP2022514591A JP2022547483A5 JP 2022547483 A5 JP2022547483 A5 JP 2022547483A5 JP 2022514591 A JP2022514591 A JP 2022514591A JP 2022514591 A JP2022514591 A JP 2022514591A JP 2022547483 A5 JP2022547483 A5 JP 2022547483A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
binding
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022514591A
Other languages
English (en)
Japanese (ja)
Other versions
JP7743396B2 (ja
JP2022547483A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/049110 external-priority patent/WO2021046159A1/en
Publication of JP2022547483A publication Critical patent/JP2022547483A/ja
Publication of JP2022547483A5 publication Critical patent/JP2022547483A5/ja
Priority to JP2025149866A priority Critical patent/JP2026009894A/ja
Application granted granted Critical
Publication of JP7743396B2 publication Critical patent/JP7743396B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022514591A 2019-09-04 2020-09-03 Ｃｄ８結合性作用剤およびその使用 Active JP7743396B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025149866A JP2026009894A (ja) 2019-09-04 2025-09-10 Ｃｄ８結合性作用剤およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962895865P 2019-09-04 2019-09-04
US62/895,865 2019-09-04
PCT/US2020/049110 WO2021046159A1 (en) 2019-09-04 2020-09-03 Cd8 binding agents and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025149866A Division JP2026009894A (ja) 2019-09-04 2025-09-10 Ｃｄ８結合性作用剤およびその使用

Publications (3)

Publication Number Publication Date
JP2022547483A JP2022547483A (ja) 2022-11-14
JP2022547483A5 true JP2022547483A5 (enExample) 2023-09-11
JP7743396B2 JP7743396B2 (ja) 2025-09-24

Family

ID=72561949

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022514591A Active JP7743396B2 (ja) 2019-09-04 2020-09-03 Ｃｄ８結合性作用剤およびその使用
JP2025149866A Pending JP2026009894A (ja) 2019-09-04 2025-09-10 Ｃｄ８結合性作用剤およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025149866A Pending JP2026009894A (ja) 2019-09-04 2025-09-10 Ｃｄ８結合性作用剤およびその使用

Country Status (15)

Country Link
US (1) US20230192853A1 (enExample)
EP (1) EP4025608A1 (enExample)
JP (2) JP7743396B2 (enExample)
KR (1) KR20220057563A (enExample)
CN (2) CN114616250B (enExample)
AR (1) AR119887A1 (enExample)
AU (1) AU2020341458A1 (enExample)
BR (1) BR112022003998A2 (enExample)
CA (1) CA3152528A1 (enExample)
CR (1) CR20220095A (enExample)
IL (1) IL291007A (enExample)
MX (1) MX2022002738A (enExample)
PE (1) PE20221449A1 (enExample)
TW (2) TW202519557A (enExample)
WO (1) WO2021046159A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114230665B (zh) * 2021-06-23 2024-03-22 苏州智核生物医药科技有限公司 CD8α结合多肽及其用途
TW202321283A (zh) * 2021-07-20 2023-06-01 美商英伊布里克斯公司 Cd8結合多肽及其用途
KR20240095224A (ko) 2021-10-27 2024-06-25 제넨테크, 인크. 억제된 착화제의 합성
CA3255622A1 (en) * 2022-04-15 2023-10-19 Valitor, Inc. HUMANIZED MULTIVALENT PROTEIN CONJUGATES
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US20260102527A1 (en) * 2023-01-27 2026-04-16 Vrije Universiteit Brussel CD8b-BINDING POLYPEPTIDES
JP2026508657A (ja) 2023-03-16 2026-03-11 アイタブメッド カンパニー， リミテッド 多重特異性抗原結合タンパク質及びその使用
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
KR100441557B1 (ko) 1994-07-21 2005-08-05 아크조 노벨 엔.브이. 고리형케톤과산화물조성물
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
PL188959B1 (pl) 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7165698A (en) 1997-05-06 1998-11-27 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
AU1308799A (en) 1997-11-06 1999-05-31 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
CN1160338C (zh) 1998-11-19 2004-08-04 沃尼尔·朗伯公司 N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP6605506B2 (ja) * 2014-02-24 2019-11-13 ヴェンタナ メディカル システムズ， インク． ＣＤ３、ＣＤ８、ＣＤ２０及びＦｏｘＰ３の同時検出によりがんに対する免疫応答をスコア化するための方法、キット、及びシステム
WO2016065435A2 (en) 2014-10-30 2016-05-06 Katholieke Universiteit Leuven Methods for low temperature fluorine-18 radiolabeling of biomolecules
US12048753B2 (en) * 2015-10-01 2024-07-30 Whitehead Institute For Biomedical Research Labeling of antibodies
CN109071632B (zh) * 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
EP3576765B1 (en) * 2017-02-06 2025-07-16 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
EP3665201A4 (en) * 2017-08-09 2021-06-02 Orionis Biosciences, Inc. CD8 BINDERS
WO2019033043A2 (en) 2017-08-11 2019-02-14 Genentech, Inc. ANTI-CD8 ANTIBODIES AND USES THEREOF

Similar Documents

Publication Publication Date Title
US12440586B2 (en) Radiolabelled antibody fragments for use in treating cancer
JP5335651B2 (ja) インターナライジング抗ｃｄ７４抗体およびその使用方法
AU2003295166B2 (en) Immunotherapy of B cell malignancies and autoimmune disease using unconjugated antibodies and conjugated antibodies, antibody combinations and fusion proteins
KR20210087938A (ko) Cd8 이미징 구조체 및 이의 사용 방법
TW202124439A (zh) Ｃｄ８結合劑及其用途
US20180071413A1 (en) Non-invasive imaging of tumor pd-l1 expression
CN115103633B (zh) 使用多种成像剂的成像方法
CN113956357A (zh) Cd8结合多肽及其用途
HK40059336A (en) Cd8 imaging constructs and methods of use thereof
HK1256178B (en) Radiolabelled antibody fragments for use in treating cancer
HK1256178A1 (en) Radiolabelled antibody fragments for use in treating cancer
IL165753A (en) HUMANIZED MONOCLONAL ANTIBODY hPAM4, A CONJUGATE COMPRISING IT AND AN ANTIBODY COMPRISING THE SAME OR FRAGMENTS THEREOF